Comparison of integral doses to normal tissue and organs at risk between interstitial high-dose-rate brachytherapy and modern external-beam radiotherapy techniques in breast and head and neck cancer patients

被引:0
|
作者
Major, Tibor [1 ,2 ,3 ,4 ]
Polgar, Csaba [1 ,2 ,3 ,4 ]
Takacsi-Nagy, Zoltan [1 ,2 ,3 ,4 ]
机构
[1] Natl Inst Oncol, Radiotherapy Ctr, 7-9 Rath Gy U, H-1122 Budapest, Hungary
[2] Semmelwe Univ, Dept Oncol, Budapest, Hungary
[3] Natl Inst Oncol, Budapest, Hungary
[4] Natl Tumor Biol Lab, Budapest, Hungary
基金
匈牙利科学研究基金会;
关键词
Integral dose; Brachytherapy; External beam therapy; Breast cancer; Head and neck cancer; RADIATION-THERAPY; HELICAL TOMOTHERAPY; IRRADIATION; IMPACT;
D O I
10.1007/s00066-025-02382-3
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BackgroundAlthough a cornerstone of modern cancer treatment, radiotherapy (RT) is associated with a risk of secondary cancer due to irradiation of non-target tissues. Techniques such as intensity-modulated RT (IMRT), volumetric modulated RT (VMAT), and stereotactic body RT (SBRT) provide highly conformal target dose distributions and reduce doses to nearby organs at risk (OARs), albeit at the cost of larger normal tissue volumes being irradiated with lower doses. In brachytherapy (BT), the low-value isodoses cannot be changed: they are a consequence of the inverse-square law. This study evaluates and compares the normal tissue integral doses (NTIDs) delivered by BT and modern external-beam RT (EBRT) techniques in breast and head and neck (H&N) cancer patients.MethodsIncluded were the BT and IMRT plans of 34 women with early-stage breast cancer treated with interstitial high-dose-rate (HDR) BT and two groups of head and neck (H&N) patients: 38 patients with mobile tongue, floor of the mouth, and base of the tongue cancer treated definitively with interstitial HDR BT for whom VMAT treatment plans were also prepared and 20 patients with tongue and floor of the mouth tumors who received postoperative interstitial HDR BT for whom VMAT and stereotactic CyberKnife (CK, Accuray Inc., Sunnyvale, CA, USA) plans were also created. The NTIDs for three normal tissue volumes (NT_V10, NT_V5, NT_V2) and OARs were calculated and compared.ResultsBrachytherapy resulted in 39%, 32%, and 26% lower NTIDs compared to IMRT for NT_V10, NT_V5, and NT_V2, respectively, in patients with breast cancer. In H&N cancer, the NTIDs were always lower for BT compared to VMAT. The reductions in NTID achieved with BT were 45%, 36% and 27% with the same planning target volumes in BT and VMAT, and 56%, 48% and 37% with larger planning target volumes in VMAT. For CK, the NTID reductions were 54%, 49% and 41% compared to BT. In breast cases, BT resulted in a significant reduction in ipsilateral lung NTID, and in H&N cases, salivary glands NTIDs were always lower with BT than with VMAT.ConclusionFor patients with breast and head and neck cancer, interstitial BT results in lower integral dose to normal tissue and OARs compared to modern EBRT techniques. The clinical implications require further detailed investigation.
引用
收藏
页数:10
相关论文
共 48 条
  • [21] Outcomes of high dose rate interstitial boost brachytherapy after external beam radiation therapy in head and neck cancer-An Indian (single institutional) learning experience
    Patra, Niladri B.
    Goswami, Jyotirup
    Basu, Swapnendu
    Chatterjee, Kaushik
    Sarkar, Shyamal K.
    BRACHYTHERAPY, 2009, 8 (02) : 248 - 254
  • [22] Polyethylene glycol hydrogel rectal spacer implantation in patients with prostate cancer undergoing combination high-dose-rate brachytherapy and external beam radiotherapy
    Yeh, Jekwon
    Lehrich, Brandon
    Tran, Carolyn
    Mesa, Albert
    Baghdassarian, Ruben
    Yoshida, Jeffrey
    Torrey, Robert
    Gazzaniga, Michael
    Weinberg, Alan
    Chaffin, Stuart
    Ravera, John
    Tokita, Kenneth
    BRACHYTHERAPY, 2016, 15 (03) : 283 - 287
  • [23] Second primary malignancies after high-dose-rate 60Co photon or 252Cf neutron brachytherapy in conjunction with external-beam radiotherapy for endometrial cancer
    Janulionis, Ernestas
    Samerdokiene, Vitalija
    Valuckas, Konstantinas Povilas
    Atkocius, Vydmantas
    Rivard, Mark J.
    BRACHYTHERAPY, 2018, 17 (05) : 768 - 774
  • [24] Long-term outcomes of high-dose-rate brachytherapy and external beam radiotherapy without hormone therapy for high-risk localized prostate cancer
    Kamitani, Nobuhiko
    Watanabe, Kenta
    Ikeda, Naoki
    Kawata, Yujiro
    Tokiya, Ryoji
    Hayashi, Takafumi
    Miyaji, Yoshiyuki
    Tamada, Tsutomu
    Katsui, Kuniaki
    JAPANESE JOURNAL OF RADIOLOGY, 2024, 42 (11) : 1322 - 1329
  • [25] Five-year quality of life in patients with high-risk localized prostate cancer treated with external beam radiotherapy alone versus external beam radiotherapy with high-dose-rate brachytherapy boost: a prospective multicenter study
    Martinez, Evelyn
    Garin, Olatz
    Pardo, Yolanda
    Fernandez, Pablo
    Guix, Benjamin
    Gutierrez, Cristina
    Boladeras, Ana
    Ferrer, Ferran
    Hernandez, Tania
    Ayala, Adriana
    Egiguren, Mikel
    Fernandez, Gema
    Munoz, Victor
    Macias, Victor
    Pera, Joan
    Pont, Angels
    Ferrer, Montserrat
    Guedea, Ferran
    JOURNAL OF CONTEMPORARY BRACHYTHERAPY, 2021, 13 (01) : 1 - 11
  • [26] Unresectable bulky chest wall recurrent breast cancer controlled with CT-guided interstitial high-dose-rate brachytherapy and external beam radiotherapy with adjuvant hormonal therapy - case report
    Kunogi, Hiroaki
    Hsu, I-Chow
    Sasai, Keisuke
    JOURNAL OF CONTEMPORARY BRACHYTHERAPY, 2021, 13 (04) : 451 - 457
  • [27] High-dose-rate brachytherapy and hypofractionated external beam radiotherapy combined with long-term androgen deprivation therapy for very high-risk prostate cancer
    Kasahara, Takashi
    Ishizaki, Fumio
    Kazama, Akira
    Yuki, Eri
    Yamana, Kazutoshi
    Maruyama, Ryo
    Oshikane, Tomoya
    Kaidu, Motoki
    Aoyama, Hidefumi
    Bilim, Vladimir
    Nishiyama, Tsutomu
    Tomita, Yoshihiko
    INTERNATIONAL JOURNAL OF UROLOGY, 2020, 27 (09) : 800 - 806
  • [28] High-close-rate intensity modulated brachytherapy with external-beam radiotherapy improves local and biochemical control in patients with high-risk prostate cancer
    Prada, Pedro J.
    Gonzalez, Herminio
    Fernandez, Jose
    Bilbao, Pedro
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2008, 10 (07) : 415 - 421
  • [29] High-dose-rate brachytherapy combined with hypofractionated external beam radiotherapy for men with intermediate or high risk prostate cancer: analysis of short- and medium-term urinary toxicity and biochemical control
    Assis Pellizzon, Antonio Cassio
    Fogaroli, Ricardo Cesar
    Gobo Silva, Maria Leticia
    Castro, Douglas Guedes
    Maia, Maria Conte
    Lopes, Ademar
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2011, 4 (01): : 43 - 52
  • [30] Comparison of dose-escalated, image-guided radiotherapy vs. dose-escalated, high-dose-rate brachytherapy boost in a modern cohort of intermediate-risk prostate cancer patients
    Marina, Ovidiu
    Gustafson, Gary S.
    Kestin, Larry L.
    Brabbins, Donald S.
    Chen, Peter Y.
    Ye, Hong
    Martinez, Alvaro A.
    Ghilezan, Michel I.
    Wallace, Michelle
    Krauss, Daniel J.
    BRACHYTHERAPY, 2014, 13 (01) : 59 - 67